Burlingame, CA – According to filings with the U.S. Securities and Exchange Commission, Hinge Bio is raising $18,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Carin Rollins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hinge Bio

Hinge Bio, Inc. is leveraging its proprietary Flex-Hinge antibody platform to develop the next-generation of multi-functional antibodies and Fc-fusion proteins that bind targets with multi-handed cooperativity.  Hinge Bio’s streamlined non-peptidyl linkage technology enables the production of therapeutic candidates with orders-of-magnitude improved affinity, specificity and biological activity, incorporating virtually any polypeptides, including gold standard targeting domains such as natural, unmodified Fabs and/or receptors, as well as effector molecules including agonists, cytokines and growth factors.

To learn more about Hinge Bio, visit http://hingebio.com/

Contact:
Carin Rollins, Chief Executive Officer
650-488-7070
carin.rollins@hingebio.com
https://www.linkedin.com/in/carin-rollins-243a8337/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved